Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Rifaximin Versus Placebo in the Prevention of Travelers' Diarrhea

This study has been completed.
Valeant Pharmaceuticals International, Inc.
The University of Texas Health Science Center, Houston
Information provided by:
DuPont, Hurbert L., MD Identifier:
First received: December 7, 2004
Last updated: May 8, 2006
Last verified: December 2004